The mu opioid receptor: A new target for cancer therapy?

Cancer

Volumn 121, Issue 16, 2015, Pages 2681-2688

  Singleton, Patrick A ^a,b   Moss, Jonathan ^b   Karp, Daniel D ^c   Atkins, Johnique T ^c   Janku, Filip ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer progression; methylnaltrexone; mu opioid receptor; opioids

Indexed keywords

17 METHYLNALTREXONE; BEVACIZUMAB; FLUOROURACIL; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; NARCOTIC ANALGESIC AGENT; TEMSIROLIMUS; NARCOTIC ANTAGONIST; QUATERNARY AMMONIUM DERIVATIVE;

ADVANCED CANCER; BREAST CANCER; CANCER INHIBITION; CANCER PAIN; CANCER SURGERY; CHRONIC PAIN; CONCENTRATION RESPONSE; CUTANEOUS MELANOMA; DRUG POTENTIATION; DRUG TARGETING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LOW DRUG DOSE; LUNG CARCINOMA; MELANOMA; METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; PHYSIOLOGY;

ANIMALS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NALTREXONE; NARCOTIC ANTAGONISTS; NEOPLASMS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, MU;

EID: 84938738946     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29460     Document Type: Review

References (49)

1. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B., A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage. 1992; 7: 259-266.
2. Cox BM, Christie MJ, Devi L, Toll L, Traynor JR., Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol. 2015; 172: 317-323.
3. Bovill JG., Surgery for cancer: does anesthesia matter? Anesth Analg. 2010; 110: 1524-1526.
4. Snyder GL, Greenberg S., Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010; 105: 106-115.
5. Yeager MP, Rosenkranz KM., Cancer recurrence after surgery: a role for regional anesthesia? Reg Anesth Pain Med. 2010; 35: 483-484.
6. Lennon FE, Moss J, Singleton PA., The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012; 116: 940-945.
7. Buggy DJ, Borgeat A, Cata J, et al., Consensus statement from the BJA Workshop on Cancer and Anaesthesia. Br J Anaesthes. 2015; 114: 2-3.
8. Gupta K, Kshirsagar S, Chang L, et al., Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002; 62: 4491-4498.
9. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J., Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006; 72: 3-11.
10. Leo S, Nuydens R, Meert TF., Opioid-induced proliferation of vascular endothelial cells. J Pain Res. 2009; 2: 59-66.
11. Moss J, Rosow CE., Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc. 2008; 83: 1116-1130.
12. Zylla D, Gourley BL, Vang D, et al., Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013; 119: 4103-4110.
13. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA., Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012; 116: 857-867.
14. Mathew B, Lennon FE, Siegler J, et al., The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesthes Analg. 2011; 112: 558-567.
15. Zagon IS, McLaughlin PJ., Opioid antagonists inhibit the growth of metastatic murine neuroblastoma. Cancer Lett. 1983; 21: 89-94.
16. Zagon IS, McLaughlin PJ., Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983; 221: 671-673.
17. Singleton PA, Garcia JG, Moss J., Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther. 2008; 7: 1669-1679.
18. Singleton PA, Mambetsariev N, Lennon FE, et al., Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res. 2010; 2: 5.
19. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG., Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007; 37: 222-231.
20. Denlinger CE, Ikonomidis JS, Reed CE, Spinale FG., Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers. J Thorac Cardiovasc Surg. 2010; 140: 505-513.
21. Iwatsuki M, Mimori K, Yokobori T, et al., Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010; 101: 293-299.
22. Kalluri R, Weinberg RA., The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-1428.
23. Voulgari A, Pintzas A., Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009; 1796: 75-90.
24. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al., The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9: e91577.
25. Biji M, Lennon F, Siegler J, et al., The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesthes Analg. 2011; 112: 3.
26. Pelleitier M, Montplaisir S., The nude mouse: a model of deficient T-cell function. Methods Achieve Exp Pathol. 1975; 7: 149-166.
27. Welden B, Gates G, Mallari R, Garrett N., Effects of anesthetics and analgesics on natural killer cell activity. AANA J. 2009; 77: 287-292.
28. Munoz M, Rosso M, Casinello F, Covenas R., Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res Treat. 2010; 122: 601-603.
29. Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, Ben-Eliyahu S., Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology. 2001; 94: 1066-1073.
30. Wada H, Seki S, Takahashi T, et al., Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology. 2007; 106: 499-506.
31. Schlagenhauff B, Ellwanger U, Breuninger H, Stroebel W, Rassner G, Garbe C., Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res. 2000; 10: 165-169.
32. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE., Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008; 107: 325-332.
33. McLaughlin PJ, Stucki JK, Zagon IS., Modulation of the opioid growth factor ([Met]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck. Head Neck. 2012; 34: 513-519.
34. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH, Duthey B., Endogenous mu-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol. 2011; 20: 24-28.
35. Nguyen J, Luk K, Vang D, et al., Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014; 113 (suppl 1): i4-i13.
36. Zylla D, Kuskowski MA, Gupta K, Gupta P., Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer [published online ahead of print October 10, 2014]. Br J Anaesth. pii: aeu351.
37. Forbes W, Patterson C,; Salix Pharmaceuticals Inc. Relistor: Methylnaltrexone Bromide Subcutaneous Injection. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/ucm401675.pdf. Accessed March 12, 2015.
38. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002; 20: 4040-4049.
39. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY., A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012; 441: 379-386.
40. Haerian BS, Haerian MS., OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013; 14: 813-824.
41. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA., μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology. 2012; 116: 896-902.
42. Wang S, Li Y, Liu XD, Zhao CX, Yang KQ., Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol. 2013; 18: 666-669.
43. Maher DP, Wong W, White PF, et al., Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesthes. 2014; 113 (suppl 1): i88-i94.
44. Cata JP, Keerty V, Keerty D, et al., A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014; 3: 900-908.
45. Singleton PA, Moss J., Effect of perioperative opioids on cancer recurrence: a hypothesis. Future Oncol. 2010; 6: 1237-1242.
46. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J., Increased mu-opioid receptor expression in metastatic lung cancer. Br J Anaesthes. 2014; 113 (suppl 1): i103-i108.
47. Zhang YF, Xu QX, Liao LD, et al., Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma. Dis Esophagus. 2015; 28: 196-203.
48. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI., Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006; 105: 660-664.
49. Chen WK, Miao CH., The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies. PLoS One. 2013; 8: e56540.